Overview

Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

Status:
Active, not recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Sulsau-Ul Haque
Trisha Wise-Draper

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Nivolumab